Immunotherapy Combination Fails to Improve Survival in Patients With NSCLC

The phase III ARTIC trial assessing the use of two immunotherapies—durvalumab and tremelimumab—for previously treated non-small cell lung cancer (NSCLC) suffered a setback. The clinical trial failed to show that this combination improves progression-free and overall survival (the study’s primary endpoints).

This randomized, open-label, multicenter study assessed this combination, as well as durvalumab monotherapy, compared with standard of care in the third-line NSCLC setting.

According to Reuters, these findings suggests that adding chemotherapy to immunotherapy, rather than giving two immunotherapies together, is more promising. In addition, durvalumab monotherapy appeared to show some signs of efficacy, indicating that tremelimumab may offset this when combined.

Source: Reuters